Fosun Pharmaceutical: A subsidiary's drug receives approval for new indications in clinical trials.

Fosun Pharma announced that its holding subsidiary Fosun Pharma Industry has received approval from the National Medical Products Administration to conduct clinical trials for the use of Fomek in combination with anlotinib for late-stage NSCLC patients with KRAS mutations. It is planned to conduct Phase II clinical trials in China after meeting the requirements. As of February 25, 2026, the drug has been approved for two indications and launched in China, with two additional applications under prioritized review. Additionally, the drug is undergoing Phase III and Phase II clinical trials. As of January 2026, the group has invested approximately 668 million yuan in research and development for this drug. Drug development carries certain risks.